Skip to main content

REVIEW article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1448687
This article is part of the Research Topic Advances in Targeted Therapy and Biomarker Research for Endocrine-Related Cancers View all 13 articles

Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

Provisionally accepted
Yuan Gao Yuan Gao Yang Yu Yang Yu Mingqing Zhang Mingqing Zhang Wenjun Yu Wenjun Yu Lihua Kang Lihua Kang *
  • Cancer Center, The First Hospital of Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Hormone receptor-positive breast cancer may recur or metastasize years or decades after its diagnosis. Furthermore, hormone receptor expression may persist in relapsed or metastatic cancer cells. Endocrine therapy is one of the most efficacious treatments for hormone receptor-positive breast cancers. Nevertheless, a considerable proportion of patients develop resistance to endocrine therapy. Previous studies have identified numerous mechanisms underlying drug resistance, such as epigenetic abnormalities in the estrogen receptor (ER) genome, activation of ERindependent ligands, and alterations in signaling pathways including PI3K/AKT/mTOR, Notch, NF-κB, FGFR, and IRE1-XBP1. This article reviews the mechanisms of endocrine resistance in hormone receptor-positive advanced breast cancer, drawing from previous studies, and discusses the latest research advancements and prospects.

    Keywords: breast cancer, Hormone receptor-positive, endocrine treatment, Resistance, mechanisms

    Received: 14 Jun 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Gao, Yu, Zhang, Yu and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lihua Kang, Cancer Center, The First Hospital of Jilin University, Changchun, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.